Emicizumab
Emicizumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Hemophilia A。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
15 项
全球在招研究
6 项
已进入 III/IV 期
27 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Emory University
- Sanofi
- Hoffmann-La Roche
- Wayne State University
- Indiana Hemophilia &Thrombosis Center, Inc.
- Hospices Civils de Lyon
- American Thrombosis and Hemostasis Network
- Christoph Königs
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、比利时、加拿大、Colombia、法国、德国、意大利、日本、荷兰、Poland、South Africa、西班牙
正在招募患者的 Emicizumab 研究
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
III 期招募中美国比利时加拿大ColombiaNCT06998524Treatment of Hemophilia A Patients With FVIII Inhibitors
不适用招募中美国德国NCT04023019Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
不适用招募中美国NCT05022459Hemlibra in Mild Hemophilia A
IV 期招募中美国NCT04567511Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)
不适用招募中法国NCT07723560ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
不适用招募中美国NCT04398628Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
不适用招募中德国NCT05802836Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
I 期招募中美国NCT05500807Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
IV 期招募中美国Croatia芬兰法国NCT05935358TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies
不适用招募中美国NCT07692217A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)
不适用招募中美国NCT07582276SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
III 期招募中美国NCT04563520A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
III 期招募中美国Argentina澳大利亚比利时NCT07416604A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
I 期招募中美国IndiaTurkey (Türkiye)NCT06703606A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
IV 期招募中美国中国台湾NCT06145373
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。